TMCnet

AskBio's Viralgen to Supply Commercial-Scale Drug Product for REGENERATE-PD Investigational Gene Therapy Phase II Trial for Parkinson's Disease

Ametefgene parvec (AB-1005) manufactured at Viralgen commercial manufacturing facility with next-generation process to deliver high-purity product with greater efficiency   AskBio Inc. (AskBio), a ...
Medical Xpress

Nervous System Diseases: News and Research on Multiple System Atrophy

A team of researchers from NYU Abu Dhabi and the University of Denver has identified a promising small molecule that could help slow or halt the progression of serious brain diseases such as Parkinson ...
The Manila Times

Alterity Therapeutics to Host Virtual KOL Event to Share New Insights on ATH434 for the Treatment of Multiple System Atrophy

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ('Alterity” or 'the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today ...
Seeking Alpha

Alterity Therapeutics Presents New Data on Multiple System Atrophy, a Rare Parkinsonian Disorder

- Data Presented at the International Congress of Parkinson’s Disease and Movement Disorders - The posters presented from Alterity’s bioMUSE study address the need for incorporating biomarkers as a ...
Kaleido Scope

Interferon-gamma drives brain pathology in a mouse model of multiple system atrophy

In 2020, Ashley Harms, Ph.D., and University of Alabama at Birmingham colleagues published an Acta Neuropathologica study that used a mouse model to show that the alpha-synuclein pathology from ...
Seeking Alpha

Alterity Therapeutics Announces Presentation on Tracking the Progression of Multiple System Atrophy at International Symposium

MELBOURNE, Australia and SAN FRANCISCO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying ...
Nature

Sensitivity and specificity of a seed amplification assay for diagnosis of multiple system atrophy: a multicentre cohort study

The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...
Nasdaq

Alterity Therapeutics Recognizes Multiple System Atrophy (MSA) Awareness Month in March and the Urgent Need for Disease-Modifying Treatments

– Company is advancing ATH434 in late-stage clinical development for Multiple System Atrophy, a rapidly progressive neurodegenerative disease with no approved therapies – MSA is a progressive ...

Lundbeck to showcase new neurology data at the American Academy of Neurology Annual Meeting

H. Lundbeck A/S (Lundbeck) today announced that new data across its neurology portfolio will be presented at the American Academy of Neurology (AAN) Annual Meeting 2026, taking place April 18–22 in ...
Mena FN

Multiple System Atrophy Market: High-Growth Opportunities For Investors To 2034 Delveinsight Ionis Pharma, Biohaven Pharma, Lundbeck A/S, Alterity Therapeutics, Theravance ...

(MENAFN- GetNews) The Key Multiple System Atrophy Companies in the market include - Teva Pharmaceutical/MODAG GmBH, H. Lundbeck A/S/Genmab, Alterity Therapeutics, Theravance Biopharma, Ionis ...
Medical Xpress

Nervous System Diseases: News and Research on Multiple System Atrophy

A new study by the University of Turku and Turku University Hospital, Finland, found that a significant proportion of Parkinson's disease diagnoses are later corrected. Up to one in six diagnoses ...